507 HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): PROGNOSTIC VALUE OF CIRCULATING TUMOR CELLS

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research1 Apr 2011507 HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): PROGNOSTIC VALUE OF CIRCULATING TUMOR CELLS Ettore De Berardinis, Gian Maria Busetto, Arianna Petracce, Chiara Nicolazzo, Paola Gazzaniga, and Vincenzo Gentile Ettore De BerardinisEttore De Berardinis Roma, Italy More articles by this author , Gian Maria BusettoGian Maria Busetto Roma, Italy More articles by this author , Arianna PetracceArianna Petracce Roma, Italy More articles by this author , Chiara NicolazzoChiara Nicolazzo Roma, Italy More articles by this author , Paola GazzanigaPaola Gazzaniga Roma, Italy More articles by this author , and Vincenzo GentileVincenzo Gentile Roma, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1203AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The prognosis of T1G3 bladder cancer is highly variable and not predictable basing upon clinical and pathological prognostic factors. There is need for improvement in risk stratification in this population; understanding the molecular profile of individual patients could provide a more personalized and tailored treatment. Main objective was to evaluate the prognostic significance of Survivin in tumor tissues and that of Survivin expressing circulating tumor cells (CTCs) in T1G3 tumors. METHODS 141 patients with T1G3 non muscle invasive ladder cancer (NMIBC) were enrolled. Additional inclusion criteria were: absence of CIS and multifocality. Planned follow up was 24 mo. Survivin was evaluated by RT-PCR in tumoral tissues. CTCs were isolated from blood by CELLection™ Dynabeads coated with the monoclonal antibody towards the human Epithelial Cell Adhesion Molecule. Cells were lysed and Dynabeads Oligo(dT) was used to capture poly A_mRNA. cDNA was synthesised and analysed for the expression of CD45, CK8 and Survivin. The primary end point was disease free survival (DFS); the favourable group at 24 mo was defined as that without any clinical evidence of disease (NED); the unfavourable group was that with evidence of recurrent disease (RD) or progressive disease (PD). Tumoral Survivin expression and presence of CTC were correlated to DFS. Multivariate nalysis was used to investigate whether CTC presence was independent indicator of DFS. RESULTS Survivin was found in about 50% of tumors. Survivin - patients showed a longer DFS than Survivin + (/2:4.572; p=0.029). CTCs were found in 51/141 patients (47%); 94% of CTC were Survivin expressing. The difference in DFS between CTC - and CTC + patients was statistically significant (/2: 28.098; p<0.001). CTC presence was found an independent prognostic factor of DFS (p<0.001). CONCLUSIONS CTC presence is an independent prognostic factor in high risk NMIBC patients. In the future will be important the count of CTC and this will allow us to establish the correlation between CTC number and prognosis. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e205-e206 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ettore De Berardinis Roma, Italy More articles by this author Gian Maria Busetto Roma, Italy More articles by this author Arianna Petracce Roma, Italy More articles by this author Chiara Nicolazzo Roma, Italy More articles by this author Paola Gazzaniga Roma, Italy More articles by this author Vincenzo Gentile Roma, Italy More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...